QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-1.82%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-1.82%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-1.82%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
QQQ   293.34 (+1.95%)
AAPL   143.96 (+1.48%)
MSFT   248.00 (+3.07%)
META   147.30 (+4.10%)
GOOGL   97.52 (+2.42%)
AMZN   99.22 (+2.10%)
TSLA   160.27 (+10.97%)
NVDA   198.02 (+2.48%)
NIO   12.17 (+4.64%)
BABA   120.57 (+0.27%)
AMD   75.16 (+0.33%)
T   20.00 (-2.06%)
MU   62.80 (+2.05%)
F   12.92 (+1.02%)
CGC   2.76 (+0.00%)
GE   81.14 (+0.43%)
DIS   109.70 (+1.46%)
AMC   5.28 (-0.94%)
PFE   44.25 (-1.82%)
PYPL   80.81 (+2.16%)
NFLX   364.87 (-0.84%)
NASDAQ:LGND

Ligand Pharmaceuticals - LGND Stock Forecast, Price & News

$69.72
-6.89 (-8.99%)
(As of 01/26/2023 05:35 PM ET)
Add
Compare
Today's Range
$69.00
$78.00
50-Day Range
$62.15
$78.50
52-Week Range
$57.77
$128.51
Volume
186,094 shs
Average Volume
113,206 shs
Market Capitalization
$1.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$119.00

Ligand Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
70.7% Upside
$119.00 Price Target
Short Interest
Bearish
5.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
1.39mentions of Ligand Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$1.53 M Sold Last Quarter
Proj. Earnings Growth
-44.68%
From $2.35 to $1.30 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

144th out of 1,048 stocks

Pharmaceutical Preparations Industry

62nd out of 513 stocks


LGND stock logo

About Ligand Pharmaceuticals (NASDAQ:LGND) Stock

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is based in San Diego, California.

Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Stock News Headlines

Stocks News Announcement
Don't miss this update. Read the press release about Small Pharma.
Ligand Pharma Guides FY23 EPS Above View, But Revenue Shy Of Estimates
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is BioNTech (BNTX) Stock Undervalued Right Now?
LGND or GMAB: Which Is the Better Value Stock Right Now?
Ligand Pharma Issues Mixed Guidance For FY23
Ligand Pharmaceuticals CEO Higgins Retires
Ligand to Hold Investor and Analyst Day on December 13
Ligand Pharmaceuticals Inc Q3 Profit Decreases, but beats estimates
Ligand Reports Third Quarter 2022 Financial Results
Ligand Announces Completion of OmniAb Spin-Off
See More Headlines
Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LGND Company Calendar

Last Earnings
11/07/2022
Today
1/26/2023
Next Earnings (Estimated)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LGND
CUSIP
53220K50
Employees
154
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$119.00
High Stock Price Forecast
$160.00
Low Stock Price Forecast
$90.00
Forecasted Upside/Downside
+70.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$57.14 million
Pretax Margin
-11.15%

Debt

Sales & Book Value

Annual Sales
$277.13 million
Cash Flow
$8.49 per share
Book Value
$49.14 per share

Miscellaneous

Free Float
15,137,000
Market Cap
$1.18 billion
Optionable
Optionable
Beta
1.10

Key Executives

  • Mr. Todd C. Davis (Age 62)
    CEO & Director
    Comp: $65.05k
  • Mr. Matthew E. Korenberg (Age 48)
    Pres & COO
    Comp: $753.25k
  • Mr. Octavio Espinoza
    Chief Financial Officer
  • Simon Latimer
    Head of Investor Relations
  • Mr. Andrew T. Reardon J.D.
    Chief Legal Officer
  • Mr. Todd Pettingill
    Director of Corp. Devel.
  • Ms. Audrey Warfield-Graham
    Chief People Officer
  • Dr. Keith Marschke
    Sr. VP of Biology & Scientific Affairs
  • Dr. Vincent D. Antle (Age 54)
    Sr. VP of Technical Operations & QA - Capitsol
  • Mr. Patrick Lucy
    Sr. VP & CBO Protein Expression Bus.













LGND Stock - Frequently Asked Questions

Should I buy or sell Ligand Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares.
View LGND analyst ratings
or view top-rated stocks.

What is Ligand Pharmaceuticals' stock price forecast for 2023?

4 brokers have issued 1 year price targets for Ligand Pharmaceuticals' shares. Their LGND share price forecasts range from $90.00 to $160.00. On average, they anticipate the company's stock price to reach $119.00 in the next twelve months. This suggests a possible upside of 55.3% from the stock's current price.
View analysts price targets for LGND
or view top-rated stocks among Wall Street analysts.

How have LGND shares performed in 2023?

Ligand Pharmaceuticals' stock was trading at $66.80 at the beginning of the year. Since then, LGND stock has increased by 14.7% and is now trading at $76.61.
View the best growth stocks for 2023 here
.

When is Ligand Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our LGND earnings forecast
.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) released its quarterly earnings data on Monday, November, 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.29. The biotechnology company earned $66.09 million during the quarter, compared to analyst estimates of $38.47 million. Ligand Pharmaceuticals had a negative net margin of 8.62% and a positive trailing twelve-month return on equity of 2.57%.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, December, 21st. The company provided earnings per share guidance of $4.30-$4.45 for the period, compared to the consensus earnings per share estimate of $4.24. The company issued revenue guidance of $184.00 million-$189.00 million, compared to the consensus revenue estimate of $212.82 million.

What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO?

1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD).

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Villere ST Denis J & Co. LLC (2.86%), Chicago Capital LLC (1.89%), Woodstock Corp (0.33%), Allspring Global Investments Holdings LLC (0.17%), AMI Asset Management Corp (0.12%) and Yousif Capital Management LLC (0.06%). Insiders that own company stock include Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza and Todd C Davis.
View institutional ownership trends
.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $76.61.

How much money does Ligand Pharmaceuticals make?

Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.29 billion and generates $277.13 million in revenue each year. The biotechnology company earns $57.14 million in net income (profit) each year or ($1.24) on an earnings per share basis.

How many employees does Ligand Pharmaceuticals have?

The company employs 154 workers across the globe.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826.

This page (NASDAQ:LGND) was last updated on 1/26/2023 by MarketBeat.com Staff